ArticleMolecular biology reports2025
The beneficial effects of dose-dependent myricetin application on renal ischemia and reperfusion injury in a rat model.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Model.Advances in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study was aimed to evaluate the renoprotective effects of Myricetin at two dosages (50 and 100 mg/kg) within an experimental I/R injury model. The analysis focused on key immunological and oxidative stress pathways, including the regulation of pro- and anti-inflammatory cytokines, NF-κB and TLR4 signaling, as well as biomarkers of oxidative stress such as nitrate (NO), malondialdehyde (MDA), glutathione (GSH), nuclear factor (erythroid-derived 2)-like 2 (NRF2) and Heme oxygenase-1 (HO-1). METHODS AND
resultsThirty female Wistar albino rats were randomly assigned to six groups. Myricetin was administered via intragastric gavage for seven days before ischemia/reperfusion. Renal ischemia was induced by clamping the left renal pedicle for 45 min, followed by a 3-hour reperfusion period. Kidney tissues were collected for histopathological, immunohistochemical, and biochemical analyses. Serum cytokine levels were measured by ELISA, while protein expressions were evaluated by Western blotting. I/R injury significantly increased pro-inflammatory cytokines and oxidative stress markers, alongside heightened NF-κB immunopositivity and TNF-α, IL-1β expression. Myricetin administration reduced pro-inflammatory cytokines, increased anti-inflammatory cytokines, and enhanced antioxidant responses. Immunohistochemical and Western blot analyses showed decreased NF-κB positivity and increased NRF2 expression.
conclusionsThe renoprotective effects of Myricetin appear to be mediated by inhibiting the NF-κB pathway, reducing inflammation, and enhancing antioxidant responses. Furthermore, Myricetin activates the NRF2/HO-1 pathway, suggesting its potential as a therapeutic agent for ischemia/reperfusion-induced kidney injury.
Indexed as
Identifiers
40956366What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.